User:Celling it/Lymphokine-activated killer cell

= Article Draft =

Cancer Treatments
LAK cell therapy is a method that uses interleukin 2 (IL-2) to enhance the number of lymphocytes in an in vitro setting, and it has formed the foundation of many immunotherapy assays that are now in use. LAK cells have shown potential as a cellular agent for cancer therapy and have been utilized therapeutically in association with IL-2 for the treatment of various cancers. LAK cells have anticancer efficacy against homologous carcinoma cells and can grow ex vivo in the presence of IL-2. In melanoma and gastric cancer cells, intercellular adhesion molecule 1 (ICAM-1) antibody can significantly inhibit in vitro LAK-induced lysis of cancer cells. A study has shown that ICAM1 in lung cancer cells increases LAK cell-mediated tumor cell death as a new anti-tumor mechanism.

Evaluation of Lymphokine-activated killer cell
The link to the article - Lymphokine-activated killer cell. The lead section should have more information about the topics/cells which are related to the LAK cells like, its relation with dendritic cells, lung cancer cells, and breast cancer cells. The article is also missing some important information about IL-2 that is critical in LAK cells activity. Also the references used in the article are not up-to-date. Many researches have been done related to LAK cells that have not been included in the article, which definitely should be present in the article. The name of research articles that I will be using to update this article are CAR T cells: continuation in a revolution of immunotherapy, Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats, Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites, A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity, Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1, and many others.